Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma.

Author(s): Jankowitz R, Joyce J, Jacobs SA

Affiliation(s): UPMC Cancer Centers, UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, USA.

Publication date & source: 2008-02, Clin Nucl Med., 33(2):94-6.

Publication type: Case Reports

We report an anaphylactic reaction in a 45-year-old gentleman with an 8-year history of extensively treated, relapsing follicular lymphoma who was receiving a second treatment with ibritumomab tiuxetan. Within seconds of receiving Y-90 ibritumomab, he developed chest tightness, shallow respirations, hypotension, and incontinence. After successful resuscitation, a human antimouse antibody (HAMA) level was found to be elevated, 618 ng/mL (reference 0-188 ng/mL).